TRAV31

Across TCGA pan-cancer cohorts, TRAV31 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated TRAV31 data layer.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher TRAV31 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRAV31 expression acts as an unfavorable survival marker, although some lineages such as LAML show a favorable association.

READ, CESC, and GBM are the cancer types where TRAV31 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	DFS	Tertile	All	0.588	0.866	.004	54	view →
CESC	OS	Tertile	IV	0.121	0.591	.029	42	view →
GBM	OS	Tertile	All	0.020	0.416	<.001	36	view →
LAML	DFS	Tertile	All	0.666	0.329	<.001	36	view →
STAD	DFS	Tertile	IV	0.097	0.412	.008	18	view →
BRCA	OS	Tertile	III,IV	0.787	0.908	.021	12	view →
SKCM	OS	Tertile	All	0.648	0.880	.001	12	view →
KIRC	DFS	Tertile	II,III,IV	0.302	0.529	.033	12	view →
PAAD	OS	Tertile	All	0.210	0.474	.007	9	view →
CHOL	OS	Tertile	All	0.155	0.725	.029	9	view →
THCA	DFS	Tertile	III,IV	0.165	0.746	.024	9	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

TRAV31–READ (DFS)

Open the READ breakdown →